CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Several novel cell-based immunotherapies have been introduced in recent years that can significantly improve survival of patients with multiple myeloma. Most recently, two CAR T-cell therapies, idecabtagene vicleucel (ida-cel) and ciltacabtagene autoleucel (cilta-cel), were approved for the treatment of multiple myeloma in patients who did not respond to multiple other lines of therapy.

In this ReCAP, Dr Joseph Mikhael, of City of Hope Cancer Center and the International Myeloma Foundation in Phoenix, Arizona, discusses the clinical trials demonstrating response rates for ida-cel and cilta-cel therapies of 81% and 98%, respectively. He also examines the differences between the two, including production time and toxicities, and the factors involved in the choice to use either CAR T-cell therapy.

Finally, he discusses the importance of improving access to new therapies and comments on the future of multiple myeloma treatments, including other potential CAR T-cell targets.

Medscape © 2023 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma - Medscape - Apr 03, 2023.